Sirukumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL6 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
1194585-53-9  |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6450H9926N1690O1998S46 |
| Molar mass | 144.6 kg/mol |
 (what is this?) (verify) | |
Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor and has started clinical trials.[2] and reported some phase II results.[3]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[4]
The drug is currently in phase II clinical trials for the treatment of depression.
See also
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
- ↑ A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy, clinicaltrials.gov
- ↑ Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
- ↑ Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis. Dec 2015
This article is issued from Wikipedia - version of the 10/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.